India, June 26 -- Avalon GloboCare (ALBT) has entered into an agreement with Qi Diagnostics to co-develop a volatile organic compound nanosensor-based point-of-care cannabis breathalyzer. Avalon, Q&A Distribution, a subsidiary of Avalon, and Qi will jointly design, validate, and develop a prototype for the cannabis breathalyzer device, which is aimed at supporting real-time detection of potential cannabis-impaired driving.
David Jin, President and CEO of Avalon GloboCare, said: "By combining Avalon's regulatory expertise with Qi Diagnostics' VOC nanosensor technology, we aim to provide a real-time, non-invasive cannabis detection solution that can support law enforcement and workplace safety."
Shares of Avalon are up 20% in pre-market tra...